ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Lupin Ltd.

  • 762.65 INR
  • -1.80
  • -0.24%
  • India
    Jul 15, 2019
  • Ticker
    BOM(500257)
  • Prev. close
    764.45
  • Market cap (INR)
    345,983M
  • Market cap (USD)
    5,047.34M
  • Shares
    452.59M

Company Background

Lupin is a major generic drugmaker that conducts business in more than 100 countries. Among India's five biggest pharmaceuticals, it has about 10 production bases in India and exports generic drugs to other countries.

It was founded in 1968 by Desh Bandhu Gupta, a researcher at a science university. Since the early 2000s, it has been actively buying companies in South Africa, Mexico, even Japan.

It got a head start on its Indian competitors by building a supply network in Japan. It did so in 2007 by acquiring Kyowa Pharmaceutical Industry, an Osaka-based medium-size generic drugmaker. In 2014, it set up a venture with Yoshindo, a generic drug company based in Japan's Toyama Prefecture, to jointly develop generic biomedicines.

Zyma Laboratories, an affiliate company run by Desh Bandhu Gupta and other executives, is Lupin's top shareholder; the founding family still owns some shares in Lupin.

Business Summary

Lupin Ltd. engages in the manufacture of pharmaceutical products. Its offers branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The firm caters to the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drug therapy, anti-tuberculosis, and cephalosporins industry segments. It operates through the following geographical segments: India, USA, Japan, and Others. The company was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.

Financial Highlights

Mar 2019 INRUSD
Revenue167,181.80M2,390.26M
Gross Profit66,360.90M948.78M
Operating income17,972.10M256.95M
Income before tax15,171.70M216.91M
Net income6,065.50M86.72M
EBITDA28,822.20M412.08M
Diluted EPS13.360.19
Dividends Per Share----
Total Assets279,493.70M4,034.55M
Total liabilities141,602.80M2,044.06M
Total equity137,422.30M1,983.72M
Operating cash flow----
Currency in INRCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 125,988.70M 137,818.50M 170,090.50M 155,509.10M 167,181.80M
Gross Profit 59,588.70M 67,159.10M 83,802.20M 60,769.20M 66,360.90M
Operating income 31,579.50M 32,615.50M 33,543.30M 18,628.40M 17,972.10M
Income before tax 34,148.30M 33,239.40M 35,348.90M 5,432.90M 15,171.70M
Net income 24,032.40M 22,607.40M 25,574.60M 2,512.60M 6,065.50M
EBITDA 35,926.50M 37,486.80M 42,665.60M 29,487.10M 28,822.20M
Diluted EPS 53.20 49.93 56.46 5.54 13.36
Dividends Per Share 7.50 7.50 7.50 5 --
Total Assets 132,271.80M 226,248.60M 266,072.80M 263,053.80M 279,493.70M
Total liabilities 43,290.20M 114,294.10M 130,751.90M 126,882.40M 141,602.80M
Total equity 88,731.40M 111,624.50M 134,966.50M 135,761.40M 137,422.30M
Operating cash flow 27,947M -4,269.70M 40,092.80M 15,901M --
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 2,060.54M 2,105.03M 2,536.50M 2,412.26M 2,390.26M
Gross Profit 974.57M 1,025.78M 1,249.71M 942.65M 948.78M
Operating income 516.48M 498.16M 500.22M 288.96M 256.95M
Income before tax 558.49M 507.69M 527.14M 84.27M 216.91M
Net income 393.04M 345.30M 381.38M 38.97M 86.72M
EBITDA 587.57M 572.57M 636.25M 457.40M 412.08M
Diluted EPS 0.87 0.76 0.84 0.08 0.19
Dividends Per Share 0.12 0.11 0.11 0.07 --
Total Assets 2,113.60M 3,416.49M 4,097.52M 4,033.22M 4,034.55M
Total liabilities 691.74M 1,725.91M 2,013.58M 1,945.40M 2,044.06M
Total equity 1,417.85M 1,685.59M 2,078.48M 2,081.53M 1,983.72M
Operating cash flow 457.07M -65.21M 597.89M 246.65M --

Valuation Measures

Mar 2019
PER55.11
ROA2.23%
ROE4.44%
Operating margin10.75%
Profit margin3.62%

Key executives

  • Managing Director & Executive Director: Nilesh Deshbandhu Gupta
  • Chief Executive Officer & Executive Director: Vinita D. Gupta
  • Chief Financial Officer: Sunil Makharia
  • President-Technical Operations: Alok Ghosh
  • President-Asia Pacific & Japan Region: Fabrice Egros

Shareholders

  • Lupin Investments Pvt Ltd. (45.4%)
  • Life Insurance Corp. of India (2.4%)
  • JHUNJHUNWALA RAKESH RADHESHYAM (1.9%)
  • The Vanguard Group, Inc. (1.7%)
  • Comgest SA (1.5%)
  • Norges Bank Investment Management (1.4%)
  • BlackRock Fund Advisors (1.4%)
  • SBI Funds Management Pvt Ltd. (1.1%)
  • FIL Investment Management (Singapore) Ltd. (1.0%)
  • Franklin Templeton Asset Management (India) Pvt Ltd. (1.0%)

Contact Details

  • Website:http://www.lupinworld.com
  • Address: B/4 Laxmi Towers, Bandra Kurla Complex, Mumbai, 400051, India
  • Phone: +91.22.66402222

Related Companies

  • Lupin Atlantis Holdings SA
  • Lupin Farmaceutica Do Brasil Ltda.
  • Lupin Pharmaceuticals Ltd/Brazil/
  • Lupin Employees Benefit Trust
  • Nanomi BV
  • Lupin Healthcare Ltd.
  • GAVIS Pharmaceuticals LLC
  • Lupin Chemical (Thailand) Ltd.
  • Lupin Holdings B.V., Netherlands
  • Polynova Industries Ltd.
  • Lupin Laboratories Ltd.
  • Laboratorios Grin SA de CV
  • Lupin Pharmaceuticals, Inc.
  • Multicare Pharmaceuticals Philippines, Inc.
  • Pharma Dynamics Pty Ltd.
  • Hormosan Pharma GmbH
  • Kyowa Pharmaceutical Industry Co., Ltd.
  • Rubamin Laboratories Ltd.
  • Lupin Chemicals Ltd.
  • Temmler Pharma GmbH & Co. KG
  • Lupin Herbal Pvt. Ltd.

Competitors

  • Mylan N.V.
  • Teva Pharmaceutical Industries Limited
  • Novartis AG
  • Aurobindo Pharma Ltd
  • Amneal Pharmaceuticals, Inc. Class A
  • Dr. Reddy's Laboratories Ltd.
  • Perrigo Co. Plc
  • Sun Pharmaceutical Industries Limited
  • Biocon Limited
  • Coherus BioSciences, Inc.
  • Gemphire Therapeutics Inc.
  • Momenta Pharmaceuticals, Inc.
  • Midatech Pharma Plc
  • Agile Therapeutics, Inc.
  • Dare Bioscience, Inc.
Last Updated on 15 Jul, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media